ELUT

Elutia Inc. Class A Common Stock (ELUT) | Rumor.io

Elutia

ELUT

Attention (50-day avg)0%

Attention rank (50-day avg)#4,452

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.64

Market capitalization35.9M

Earnings per share-0.63

Dividend yield (TTM)—

Revenue (annual)12.3M

Net income (annual)53.4M

Social

What share of all stock conversation is about ELUT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 16

Elutia Inc. has agreed to sell its SimpliDerm business to Cellution Biologics for up to $11 million, with $8 million paid at closing and up to $3 million in milestone payments.
The deal is expected to close in H2 2026, and will help Elutia focus on its NXT-41x launch, a next-gen biomatrix targeting the $1.5 billion plastic and aesthetic market.
The sale will also enhance Elutia's balance sheet, providing liquidity without diluting shareholder ownership.

Generated by AI

Sentiment

Of the messages about ELUT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.67% +49.39
Bearish	—	—	—	3.33% -49.39

Bullish· Sep 19

$ELUT is expected to maintain an 8-10 price range and is considered a "wild card" with strong volume and chart support.
The stock's easy borrowability and enticing short positions may lead to a price squeeze, potentially driving the stock up to $2.20.
$ELUT is gaining momentum and is considered a strong premarket runner, with some investors already seeing potential for a breakout and expecting further gains.

Bearish· Mar 23

The company's stock price may be manipulated by the company's executives, who could be selling shares at high prices.
The asset's price may be influenced by a large float and significant volume, which could lead to rapid price drops.
The company's financial health may be negatively impacted by a lawsuit, specifically the fibercel litigation, which could affect its balance sheet.

Generated by AI

Topics

Of the messages about ELUT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	62.16%
Analysts	—	—	0%	0%
Controversies	—	—	0%	1.8%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	36.04%

Sep 19

Elutia Inc. (ELUT) will receive up to $35 million in cash proceeds from the sale of its Orthobiologics business unit, with an additional $15 million upfront payment.
The company has also announced a private placement for proceeds up to $26 million, which will be used to secure its fiscal year for 2024.
The combined proceeds from the divestiture and financing are expected to add more than $60 million in cash to Elutia's balance sheet, strengthening its financial position and extending its cash runway.

Generated by AI

Community

Of the messages about ELUT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	4.05%
Newcomers	100%	100%	100%	95.95%

Jul 16

Elutia Inc. has sold the SimpliDerm business for up to $11 million, with $8 million in cash at closing and up to $3 million in milestone payments.
The sale is expected to strengthen the company's balance sheet ahead of the launch of NXT-41x, a next-generation biomatrix targeting the $1.5 billion plastic and aesthetics market.
Elutia will focus on NXT-41x following the sale, with a commercial launch expected in 2027.

Generated by AI

News

Elutia at H.C. Wainwright conference: capital, data and launch path

19d agoInvesting.com

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

20d agoYahoo Finance

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences. Lake Street Capital Markets 10th Annual Big Ideas Growth ConferenceElutia will host one-on-one meetings with investors at the

27d agoYahoo Finance

Elutia (ELUT) Q2 2026 Earnings Call Transcript

Detailed price information for Elutia Inc (ELUT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT)

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Elutia sells SimpliDerm business for up to $11 million

1mo agoInvesting.com

Also Discussed

Investors talking about ELUT also mention

#	Name	Attention
1	XChange TEC Inc. American Depositary SharesXHG	0%0
2	TCBP - TC Biopharm (Holdings) Plc	——
3	NexGel Inc.NXGL	0%new
4	LSB - LakeShore Biopharma Co., Ltd	——
5	Lifecore Biomedical Inc.LFCR	0%-0.01
6	LIPO - Lipella Pharmaceuticals Inc.	——
7	Zura Bio LimitedZURA	0%new
8	Biomea Fusion Inc.BMEA	0.01%-0.01
9	NeuroSense Therapeutics Ltd.NRSN	0%0
10	NFTG - The NFT Gaming Company, Inc.	——

Elutia Inc. Class A Common Stock

Healthcare
Medical Devices

Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care. The company offers biologic solutions intended for procedures involving implanted electronic devices, soft tissue repair, and regenerative support. Its portfolio serves healthcare providers working across specialized surgical settings where compatibility, tissue integration, and complication reduction are important. Elutia Inc. operates as a focused player in the regenerative medicine and biomaterials market, addressing needs in implant-based procedures and reconstructive care.

Website

Location

20 Firstfield Road

Gaithersburg, MD, 20878

United States

Social

What share of all stock conversation is about ELUT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jul 16

Elutia Inc. has agreed to sell its SimpliDerm business to Cellution Biologics for up to $11 million, with $8 million paid at closing and up to $3 million in milestone payments.
The deal is expected to close in H2 2026, and will help Elutia focus on its NXT-41x launch, a next-gen biomatrix targeting the $1.5 billion plastic and aesthetic market.
The sale will also enhance Elutia's balance sheet, providing liquidity without diluting shareholder ownership.

Generated by AI

Sentiment

Of the messages about ELUT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.67% +49.39
Bearish	—	—	—	3.33% -49.39

Bullish· Sep 19

$ELUT is expected to maintain an 8-10 price range and is considered a "wild card" with strong volume and chart support.
The stock's easy borrowability and enticing short positions may lead to a price squeeze, potentially driving the stock up to $2.20.
$ELUT is gaining momentum and is considered a strong premarket runner, with some investors already seeing potential for a breakout and expecting further gains.

Bearish· Mar 23

The company's stock price may be manipulated by the company's executives, who could be selling shares at high prices.
The asset's price may be influenced by a large float and significant volume, which could lead to rapid price drops.
The company's financial health may be negatively impacted by a lawsuit, specifically the fibercel litigation, which could affect its balance sheet.

Generated by AI

Topics

Of the messages about ELUT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	62.16%
Analysts	—	—	0%	0%
Controversies	—	—	0%	1.8%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	36.04%

Sep 19

Elutia Inc. (ELUT) will receive up to $35 million in cash proceeds from the sale of its Orthobiologics business unit, with an additional $15 million upfront payment.
The company has also announced a private placement for proceeds up to $26 million, which will be used to secure its fiscal year for 2024.
The combined proceeds from the divestiture and financing are expected to add more than $60 million in cash to Elutia's balance sheet, strengthening its financial position and extending its cash runway.

Generated by AI

Community

Of the messages about ELUT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	4.05%
Newcomers	100%	100%	100%	95.95%

Jul 16

Elutia Inc. has sold the SimpliDerm business for up to $11 million, with $8 million in cash at closing and up to $3 million in milestone payments.
The sale is expected to strengthen the company's balance sheet ahead of the launch of NXT-41x, a next-generation biomatrix targeting the $1.5 billion plastic and aesthetics market.
Elutia will focus on NXT-41x following the sale, with a commercial launch expected in 2027.

Generated by AI

Elutia

Social

Jul 16

Bullish· Sep 19

Bearish· Mar 23

Sep 19

Jul 16

Elutia at H.C. Wainwright conference: capital, data and launch path

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Elutia (ELUT) Q2 2026 Earnings Call Transcript

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT)

Elutia sells SimpliDerm business for up to $11 million

Also Discussed

Elutia Inc. Class A Common Stock

Company Information

Location

Elutia at H.C. Wainwright conference: capital, data and launch path

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Elutia (ELUT) Q2 2026 Earnings Call Transcript

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT)

Elutia sells SimpliDerm business for up to $11 million

Also Discussed

Social

Jul 16

Bullish· Sep 19

Bearish· Mar 23

Sep 19

Jul 16